DLA PIPER LLP (US) for BIOTECHNOLOGY INNOVATION ORGANIZATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR | — |
| JAMIE ALEXEI GREGORIAN | — |
| KARINA LYNCH | — |
| MARGARET MARTIN | — |
| RACHEL PORTMAN | — |
| VINCENT SARUBBI | — |
Medical/Disease Research/Clinical Labs MED
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR | — |
| JAMIE ALEXEI GREGORIAN | — |
| KARINA LYNCH | — |
| MARGARET MARTIN | — |
| RACHEL PORTMAN | — |
| VINCENT SARUBBI | — |
Health Issues HCR
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR | — |
| JAMIE ALEXEI GREGORIAN | — |
| KARINA LYNCH | — |
| MARGARET MARTIN | — |
| RACHEL PORTMAN | — |
| VINCENT SARUBBI | — |
Medicare/Medicaid MMM
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BURR | — |
| JAMIE ALEXEI GREGORIAN | — |
| KARINA LYNCH | — |
| MARGARET MARTIN | — |
| RACHEL PORTMAN | — |
| VINCENT SARUBBI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.